11 results about "DNA-binding domain" patented technology

The present invention provides a method of identifying the amino acid position of a DNA modifying enzyme for insertion into a heterologous DNA binding domain (DBD), the method comprising the steps of: providing a library of DNA modifying enzymes wherein members of the library comprise heterologous amino acid sequence insertion throughout the DNA modifying enzyme; identifying those DNA modifying enzymes in the library that have DNA modifying activity; and determining insertion positions in those DNA modifying enzymes identified in the previous step. The invention also relates to a method of preparing a DNA modifying enzyme comprising an inserted heterologous DBD, a method of modifying a nucleic acid sequence in a cell, and a method of evolving a DNA binding domain for a desired target sequence. The invention also provides nucleic acid sequences encoding such DNA modifying enzymes and DNA binding domains, corresponding vectors and host cells.

The application discloses a mutant of a photosensitive protein BphP1. The application also provides a kind of optogenetic system, which comprises the fusion protein of the BphP1 mutant and the transcription activation domain (AD) of Gal4, the fusion protein of the photosensitive protein PpsR2 and the DNA binding domain (DBD) of Gal4, and the expression vector for expressing target genes through Gal1 promoter, wherein the PpsR2 can be wild type truncated variant Q-PpsR2. The induction intensity of the optimized optogenetic system of the application is 2.99 times that of the original light induction system.

The present invention is inter alia directed to a fusion protein comprising (i) an adenosine deaminase 2 (ADA2) domain and (ii) a DNA binding domain, wherein the DNA binding domain is capable of binding to a target DNA sequence; a pharmaceutical composition comprising adenosine deaminase 2 (ADA2) or a functional variant thereof and at least one pharmaceutically suitable excipient, wherein the pharmaceutical composition is targeted to the lysosome; and a pharmaceutical composition comprising adenosine deaminase 2 (ADA2) or a functional variant thereof and at least one pharmaceutically suitable excipient, wherein the pharmaceutical composition is targeted to a macrophage.

Provided are chimeric high mobility group (HMG) transcription factor polypeptides. In some aspects, provided are chimeric polypeptides comprising an N-terminal effector domain of a first HMG transcription factor and an HMG DNA binding domain and a C-terminal effector domain, wherein the HMG DNA binding domain or C-terminal effector domain is of a second HMG transcription factor. Also provided are cells (e.g., immune effector cells) that express a chimeric HMG transcription factor polypeptide of the present disclosure. In some instances, such cells (e.g., T cells) exhibit enhanced function relative to cells expressing only native wild-type HMG transcription factors. Also provided are methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

The invention discloses a transcriptional activation type RUBY visual virus infection system as well as a method and application thereof. The system is based on a betacyanin biosynthesis pathway, a transcriptional activation system is utilized, and a yeast GAL4 DNA binding domain (BD) and a herpes virus VP16 transcriptional activation domain (AD) are fused and constructed in a virus vector; when the virus infects expressed transgenic tobacco, the expression of the RUBY whole gene can be activated, so that a red signal is generated. The construction method of the system is clear, complex instruments are not needed, an efficient and convenient tool platform is provided for protein function analysis, host factor screening and infection mechanism exploration in virology research, and good expandability is achieved.

This invention provides a technology that can improve the proliferation rate of cells in cultures using microcarriers. [Solution] The cell line is established by introducing the following four genes: CDK4(R24C), TERT, CCND1, and p53 lacking the DNA binding domain into bovine progenitor cells.

The present invention relates to methods and compositions for modifying a target site in the genome of a cell. Fusion proteins including one or more DNA binding domains and one or more heterologous domains, such as DNA modifying domains, connected by improved linker sequences are provided. Codon optimized polynucleotides encoding fusion proteins including one or more DNA binding domains and one or more heterologous domains connected by improved linker sequences are provided.

The application provides a Bst DNA polymerase domain, a mutant and application thereof, and belongs to the technical field of molecular biology. The amino acid sequence of the Bst DNA polymerase domain is shown in SEQ ID NO:1. The Bst DNA polymerase mutant is obtained by replacing the natural DNA binding domain of the wild-type Bst DNA polymerase with the amino acid sequence shown in SEQ ID NO:1. The Bst DNA polymerase mutant exhibits extremely high catalytic efficiency on dUTP, and also has excellent hot-start characteristics, and can reduce the false positive rate of LAMP technology to close to zero. The Bst DNA polymerase mutant also has extremely strong complex sample tolerance, and the detection sensitivity of the pathogen is 20 times higher than that of the wild-type Bst enzyme, and can meet the early and accurate diagnosis requirements of trace infection.

The invention relates to a CAR-gamma delta T cell of a self-secreting immune cell adapter and a preparation method of the CAR-gamma delta T cell. The CAR-gamma delta T cell is prepared from a gamma delta T cell, the gamma delta T cell contains a nucleotide sequence for coding a SynNotch receptor and a nucleotide sequence for coding an effector, the SynNotch receptor comprises a transmembrane core module and an intracellular regulation and control module, the intracellular regulation and control module is connected with the C end of the transmembrane core module, and the C end of the intracellular regulation and control module is connected with the C end of the transmembrane core module. The intracellular regulation module comprises a DNA binding domain and a transcriptional regulation structural domain, and the transmembrane core module can be cut by gamma-secretase to separate the intracellular regulation module; the nucleotide sequence encoding the effector includes an upstream activation sequence capable of specifically binding to the DNA binding domain, and nucleotide fragments encoding an immune cell adapter, a self-cleaving peptide, and a T cell immune activator.

Modified filamentous fungi with improved protein productivity, and proteins using the modified filamentous fungi. Providing a manufacturing method. [Solution] An ACE3 variant is expressed, and the ACE3 variant is Zn(II)2C of ACE3. A modified filamentous fungus in which substantially all of the ys6 type DNA binding domain is missing. A method for producing proteins, including culturing filamentous fungi.

A viral gene therapy vector for removing hepatitis B virus and application, relates to the field of biological medicine, especially to a gene therapy vector and its preparation method and application. To solve the problem that the existing viral gene therapy vector can only inhibit hepatitis B virus replication and cannot remove viral cccDNA. The vector comprises a promoter, an intron, an enhancer, a PGLYRP2 protein nuclear localization signal NLS functional domain coding gene, a PGLYRP2 protein HBV DNA binding domain coding gene, a PGLYRP2 protein secretion signal peptide functional domain coding gene, a PGLYRP2 protein HBV nuclear envelope binding functional domain coding gene and an IRES fragment. The viral gene therapy vector of the application can significantly promote the removal of HBV in the liver of mice. The viral gene therapy vector of the application is used for treating hepatitis B virus infection.